Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin (2022 - 2025)

Historic FCF Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 28.57%.

  • Phathom Pharmaceuticals' FCF Margin rose 3604800.0% to 28.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 153.12%, marking a year-over-year increase of 7898400.0%. This contributed to the annual value of 483.07% for FY2024, which is 199295400.0% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' FCF Margin stood at 28.57%, which was up 3604800.0% from 158.98% recorded in Q2 2025.
  • Phathom Pharmaceuticals' FCF Margin's 5-year high stood at 1626.57% during Q1 2022, with a 5-year trough of 6491.5% in Q4 2023.
  • For the 4-year period, Phathom Pharmaceuticals' FCF Margin averaged around 771.71%, with its median value being 186.45% (2024).
  • In the last 5 years, Phathom Pharmaceuticals' FCF Margin plummeted by -69232100bps in 2023 and then soared by 62775600bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' FCF Margin (Quarter) stood at 431.71% in 2022, then crashed by -1604bps to 6491.5% in 2023, then skyrocketed by 97bps to 213.93% in 2024, then surged by 87bps to 28.57% in 2025.
  • Its FCF Margin was 28.57% in Q3 2025, compared to 158.98% in Q2 2025 and 297.96% in Q1 2025.